ASSESSING THE COMPARATIVE EFFICACY OF INP104 FOR ACUTE TREATMENT OF MIGRAINE ATTACKS: A MATCHING-ADJUSTED INDIRECT COMPARISON

被引：0
|
作者：
Joshi, S. [1 ]
Aurora, S. K. [2 ]
Wang, S. [3 ]
Park, J. E. [4 ]
Wu, P. [4 ]
Keeping, S. T. [4 ]
Bariahtaris, S. [2 ]
Shrewsbury, S. [2 ]
机构：
[1] Dent Neurol Inst, Amherst, NY USA
[2] Impel NeuroPharma Inc, Seattle, WA USA
[3] Precis HEOR, W Vancouver, BC, Canada
[4] Precis HEOR, Vancouver, BC, Canada
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND7
引用
收藏
页码：S159 / S159
页数：1
相关论文
共 50 条
  • [1] Assessing the comparative efficacy of INP104 for acute treatment of migraine attacks: A matching-adjusted indirect comparison
    Joshi, S.
    Aurora, S. K.
    Wang, S.
    Park, J. E.
    Wu, P.
    Keeping, S. T.
    Bariahtaris, S.
    Shrewsbury, S. B.
    HEADACHE, 2021, 61 : 56 - 56
  • [2] Exploratory efficacy of INP104 in migraine patients by prior treatment
    Bilchik, T. R.
    Vann, R.
    Murphy, M.
    Ray, S.
    Shrewsbury, S. B.
    Aurora, S. K.
    HEADACHE, 2022, 62 : 147 - 147
  • [3] Early prediction of response to INP104 for the acute treatment of migraine
    Sacco, S.
    Vann, R.
    Lieu, T.
    Ray, S.
    Shrewsbury, S. B.
    Aurora, S. K.
    HEADACHE, 2022, 62 : 127 - 128
  • [4] Comparative Efficacy, Quality of Life, and Safety/Tolerability of Atogepant and Rimegepant in Migraine Prevention: A Matching-Adjusted Indirect Comparison
    Tassorelli, C.
    Onishchenko, K.
    Duan, M.
    Hemstock, M.
    Voller, C.
    Gandhi, P.
    Dupont-Benjamin, L.
    HEADACHE, 2023, 63 : 122 - 123
  • [5] Comparative Efficacy, Quality of Life, and Safety/Tolerability of Atogepant and Rimegepant in Migraine Prevention: A Matching-Adjusted Indirect Comparison
    Tassorelli, Cristina
    Onishchenko, Kateryna
    Duan, Molly
    Hemstock, Matthew
    Voller, Corey
    Gandhi, Pranav
    Dupont-Benjamin, Laure
    CEPHALALGIA, 2023, 43 (1supp) : 258 - 260
  • [6] INP104: a drug evaluation of a nonoral product for the acute treatment of migraine
    Starling, Amaal J.
    Mallick-Searle, Theresa
    Shrewsbury, Stephen B.
    Aurora, Sheena K.
    PAIN MANAGEMENT, 2023, 13 (05) : 283 - 298
  • [7] Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
    Mahon, Ronan
    Tiwari, Santosh
    Koch, Mirja
    Ferraris, Matias
    Betts, Keith A.
    Wang, Yan
    Gao, Sophie
    Proot, Pascal
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (03)
  • [8] Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis
    Tassorelli, Cristina
    Onishchenko, Kateryna
    Singh, Rashmi B. Halker
    Duan, Molly
    Dupont-Benjamin, Laure
    Hemstock, Matthew
    Voller, Corey
    McAllister, Peter
    Nahas, Stephanie J.
    Gandhi, Pranav
    Ailani, Jessica
    CEPHALALGIA, 2024, 44 (02)
  • [9] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND PONESIMOD FOR RELAPSING MULTIPLE SCLEROSIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Swallow, E.
    Pham, T.
    Patterson-Lomba, O.
    Yin, L.
    Gomez-Lievano, A.
    Liu, J.
    Tencer, T.
    Gupte-Singh, K.
    VALUE IN HEALTH, 2022, 25 (07) : S300 - S300
  • [10] Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison
    Swallow, Elyse
    Pham, Timothy
    Patterson-Lomba, Oscar
    Yin, Lei
    Gomez-Lievano, Andres
    Liu, Jingyi
    Tencer, Tom
    Gupte-Singh, Komal
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
12345